CERT1 mutations perturb human development by disrupting sphingolipid homeostasis

Charlotte Gehin, Museer A. Lone, Winston Lee, Laura Capolupo, Sylvia Ho, Adekemi M. Adeyemi, Erica H. Gerkes, Alexander P. A. Stegmann, Estrella Lopez-Martin, Eva Bermejo-Sanchez, Beatriz Martinez-Delgado, Christiane Zweier, Cornelia Kraus, Bernt Popp, Vincent Strehlow, Daniel Graefe, Ina Knerr, Eppie R. Jones, Stefano Zamuner, Luciano A. AbriataVidya Kunnathully, Brandon E. Moeller, Anthony Vocat, Samuel Rommelaere, Jean-Philippe Bocquete, Evelyne Ruchti, Greta Limoni, Marine Van Campenhoudt, Samuel Bourgeat, Petra Henklein, Christian Gilissen, Bregje W. van Bon, Rolph Pfundt, Marjolein H. Willemsen, Jolanda H. Schieving, Emanuela Leonardi, Fiorenza Soli, Alessandra Murgia, Hui Guo, Qiumeng Zhang, Kun Xia, Christina R. Fagerberg, Christoph P. Beier, Martin J. Larsen, Irene Valenzuela, Paula Fernandez-alvarez, Shiyi Xiong, Robert Smigiel, Vanesa Lopez-Gonzalez, Lluis Armengol, Thorsten Hornemann*, Giovanni D'Angelo*, Vincenzo A. Gennarino*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Neural differentiation, synaptic transmission, and action potential propagation depend on membrane sphingolipids, whose metabolism is tightly regulated. Mutations in the ceramide transporter CERT (CERT1), which is involved in sphingolipid biosynthesis, are associated with intellectual disability, but the pathogenic mechanism remains obscure. Here, we characterize 31 individuals with de novo missense variants in CERT1. Several variants fall into a previously uncharacterized dimeric helical domain that enables CERT homeostatic inactivation, without which sphingolipid production goes unchecked. The clinical severity reflects the degree to which CERT autoregulation is disrupted, and inhibiting CERT pharmacologically corrects morphological and motor abnormalities in a Drosophila model of the disease, which we call ceramide transporter (CerTra) syndrome. These findings uncover a central role for CERT autoregulation in the control of sphingolipid biosynthetic flux, provide unexpected insight into the structural organization of CERT, and suggest a possible therapeutic approach for patients with CerTra syndrome.
Original languageEnglish
Article numbere165019
Number of pages17
JournalJournal of Clinical Investigation
Volume133
Issue number10
DOIs
Publication statusPublished - 15 May 2023

Keywords

  • TRANSPORT PROTEIN CERT
  • ENDOPLASMIC-RETICULUM
  • NONVESICULAR TRAFFICKING
  • SPHINGOMYELIN SYNTHASE
  • CERAMIDE TRAFFICKING
  • MASS-SPECTROMETRY
  • STRUCTURAL BASIS
  • GOLGI-APPARATUS
  • START DOMAINS
  • ASSOCIATION

Fingerprint

Dive into the research topics of 'CERT1 mutations perturb human development by disrupting sphingolipid homeostasis'. Together they form a unique fingerprint.

Cite this